Liaoning Yanyang Medical devoted nine years to industrializing the laboratory achievements of Academician Chen Hongduo's team in locally activating immunity through hyperthermia to clear HPV, pioneering a differentiated path of medical-engineering collaboration. Its core technology—precision temperature-controlled near-infrared light—maintains a tolerance margin of only 0.5°C around 44°C. This enables targeted heating of the epithelial layer where HPV resides, awakening the body's own immune response to clear the virus and producing an abscopal effect. The technology has been adopted in the dermatology departments of nearly 300 hospitals, with cumulative clinical applications exceeding 100,000 cases. In 2025, the company launched the first domestically approved visualized cervical treatment device to include high-risk cervical HPV infection as an indication, entering the cervical health track. Committed to academic leadership and evidence-based advancement, the company eschews hype and steadily expands its product line.
